0.00
—
Close of 28 Oct 2026, in USD
Search any instrument
Reference data, closing prices and charts across 45,000 companies, plus crypto, commodities and currencies.
About Rebus Holdings
Its shares trade under the ticker RBSH. It has been listed since 2 November 2009.
Rebus Holdings, Inc. is a pharmaceutical company engaged in the research and development of novel therapeutics for the treatment of cancer. The company is headquartered in Westlake Village, California. The company went IPO on 2009-11-02. The firm is focused on the research and development of targeted precision therapeutics for the treatment of cancer. The firm utilizes its proprietary delivery technology to enhance immuno-modulation for developing therapeutic outcomes. Its immune-oncology lead asset, RT-AR001, is an adenosine A2A receptor antagonist, is differentiated by its intratumoral delivery of nano- or microparticle formulations that allow for better tumor infiltration. Its patented portfolio of adenosine receptor antagonists provides treatment based on the specific adenosine targets found in each type of cancer. The adenosine receptor modulators include A2A, A2B and dual A2A/A2B antagonists, that have broad development applicability, including indications within immuno-oncology. The company is also engaged in the manufacturing of platform delivery systems for nano- or microparticle formulations that are used in toxicology studies.
Figures and description from our data supplier, not checked against the company's own report.
Company facts
- Sector
- Health Care
- Industry
- Biotechnology
- Listed since
- 2 Nov 2009
Leadership
Pay as last reported
- Mr. John MontgomeryDirector, since 2017
- Mrs. Claire ThomDirector, since 2016
- Mr. Scott OgilvieIndependent Director, since 2008
- Mr. Michael CainInterim Chief Executive Officer, Director, since 2019
- Mr. Christopher LowePresident, Chief Executive Officer, Principal Accounting Officer, Director, since 2016
- Dr. Ronald ShazerChief Medical Officer, Senior Vice President, since 2016
- Dr. Richard BullerDirector, since 2016
- Dr. Peter Grebowinterim Chairman of the Board, since 2016
- Dr. Bo HansenIndependent Director, since 2010
- Dr. Russell RichersonChief Operating Officer, since 2016$341,845
- Dr. Craig DionneChairman of the Board, President, Chief Executive Officer, Chief Financial Officer, since 2012$425,913
- Nancy BarnabeiPrincipal Accounting Officer, Vice President - Finance, Treasurer, since 2012$85,659
Environmental, social and governance
Scores out of 100, from our data supplier
- Overall
- 0
- Environment
- 0
- Social
- 0
- Governance
- 0
SWOT analysis
AI-generated by our data supplier. Not written or checked by our editors.
Strengths
- Rebus Holdings Inc. is a biotechnology company focused on cancer therapeutics research and development.
- The company utilizes proprietary delivery technology for enhanced immuno-modulation in therapeutic development.
- Rebus has a patented portfolio of adenosine receptor antagonists for targeted cancer treatments.
Weaknesses
- The company's focus on cancer therapeutics may limit diversification in product offerings.
- Rebus relies on a single lead asset, RT-AR001, for its immuno-oncology pipeline.
- The firm's manufacturing capabilities are limited to platform delivery systems for toxicology studies.
Opportunities
- Expanding the application of adenosine receptor modulators across multiple cancer indications.
- Leveraging proprietary delivery technology for broader therapeutic applications.
- Potential partnerships for development and commercialization of RT-AR001.
Threats
- Competition in the cancer therapeutics market may impact the company's market position.
- Regulatory challenges could delay or prevent approval of RT-AR001.
- Dependence on a single lead asset increases business risk if development fails.
Sources and methodology
- Data on this tab
- Our data supplier
- Chart on the Overview
- TradingView
Nothing here is investment advice. Prices can be delayed or wrong, so check with the exchange before relying on them. Data for this page. How we cover markets.